Pure Biologics S.A. Logo

Pure Biologics S.A.

Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.

PUR | WAR

Overview

Corporate Details

ISIN(s):
PLPRBLG00010 (+1 more)
LEI:
2594002TXS19AUYHIF82
Country:
Poland
Address:
WROCŁAW LEGNICKA 48E, 54-202 WROCŁAW
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pure Biologics S.A. is a biopharmaceutical company focused on the discovery and development of novel biological drugs and non-systemic therapies. The company utilizes its expertise in antibody and aptamer technologies to develop new therapeutic molecules. Its development portfolio primarily targets immuno-oncology and autoimmune diseases. A key element of its strategy is the focus on creating entirely new biological drugs, as opposed to generic or biosimilar alternatives, positioning itself as an innovator in the biotechnology sector.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-06 11:46
Share Issue/Capital Change
Deklaracja w przedmiocie objęcia akcji nowej emisji - Content (PL)
Polish 1.0 KB
2025-10-01 17:28
Pre-Annual General Meeting Information
Zmieniona treść projektów uchwał NWZ Pure Biologics S.A. zwołanego na dzień 21.…
Polish 204.2 KB
2025-10-01 17:28
Pre-Annual General Meeting Information
Zmieniona treść ogłoszenia o zwołaniu NWZ Pure Biologics S.A. na dzień 21.10.20…
Polish 200.3 KB
2025-10-01 17:28
Pre-Annual General Meeting Information
Zmiana w porządku obrad Nadzwyczajnego Walnego Zgromadzenia Pure Biologics S.A.…
Polish 1.5 KB
2025-09-30 20:01
Audit Report / Information
Raport niezależnego biegłego rewidenta z badania sprawozdania finansowego Pure …
Polish 287.3 KB
2025-09-30 20:01
Interim Report
Skrócone śródroczne sprawozdanie finansowe Pure Biologics S.A. za okres 1.01.20…
Polish 4.5 MB
2025-09-30 20:01
Interim Report
Jednostkowy raport półroczny Pure Biologics S.A. za okres 1.01.2025-30.06.2025
Polish 2.9 MB
2025-09-24 19:51
Post-Annual General Meeting Information
Treść projektów uchwał NWZ Pure Biologics S.A. zwołanego na dzień 21.10.2025
Polish 201.2 KB
2025-09-24 19:51
Pre-Annual General Meeting Information
Treść ogłoszenia o zwołaniu NWZ Pure Biologics S.A. na dzień 21.10.2025
Polish 199.2 KB
2025-09-24 19:51
Pre-Annual General Meeting Information
Informacja o zwołaniu Nadzwyczajnego Walnego Zgromadzenia Pure Biologics S.A. w…
Polish 1.3 KB
2025-09-15 17:57
Share Issue/Capital Change
Podsumowanie emisji akcji serii P1 - Content (PL)
Polish 4.1 KB
2025-09-11 18:03
Report Publication Announcement
Zmiana terminu publikacji raportu półrocznego za I półrocze 2025 r. - Content (…
Polish 863 bytes
2025-09-10 18:43
Legal Proceedings Report
Wycofanie przez Zarząd wniosku o ogłoszenie upadłości Spółki - Content (PL)
Polish 1.9 KB
2025-08-27 17:34
Share Issue/Capital Change
Przydział akcji zwykłych na okaziciela serii P1 - Content (PL)
Polish 954 bytes
2025-07-18 15:21
Share Issue/Capital Change
Zawarcie umowy inwestycyjnej z ACRX Investments Limited - Content (PL)
Polish 3.3 KB

Automate Your Workflow. Get a real-time feed of all Pure Biologics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pure Biologics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan 2927
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX

Talk to a Data Expert

Have a question? We'll get back to you promptly.